Shamburg News · 8-K filed Nov 12, 2026, 4:15 PM EST

Crescent Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights

CBIO · CRESCENT BIOPHARMA, INC.

  • Earnings
  • Materiality: high

Crescent Biopharma, Inc. reported a net loss of $37.7 million, or $0.90 per basic and diluted share, for the three months ended September 30, 2026, compared with a net loss of $24.6 million, or $1.27 per share, a year earlier. License agreement revenue for the quarter was $3,117 thousand, and R&D expenses were $34.3 million. Cash and cash equivalents were $289.4 million as of September 30, 2026, which the company expects will fund operations into the second half of 2028.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001628280-26-073409.

Written from the filing by Shamburg Markets. Figures are as reported by the company.